Compare Elevance Health Inc. Common Stock (ELV) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elevance Health Inc. Common Stock vs Hinge Health Inc. Class A Common Stock — how do they compare? Elevance Health Inc. Common Stock trades at $432 (market cap $92.23B), while Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B). The key difference: Elevance Health Inc. Common Stock is far larger — about 10.9× Hinge Health Inc. Class A Common Stock's market cap, and Elevance Health Inc. Common Stock pays a 1.62% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Elevance Health Inc. Common Stock for 1 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| ELV | HNGE | |
|---|---|---|
Market Cap | $92.23B | $8.48B |
Volume | 1,842,737 | 879,799 |
Sector | Health | Health |
52-Week High | $428.09 | $105.14 |
52-Week Low | $280.74 | $31.17 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $113.04B | $8.10B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elevance Health (ELV) trades at $425.27, up 0.75% with a bullish technical outlook and strong institutional support. The stock shows consistent earnings beats with Q1 2026 EPS of $12.58 beating expectations by 16%, while maintaining solid fundamentals with $199.13B revenue and 11.2% ROE. Recent Medicare Advantage plan announcements and positive analyst coverage reinforce growth prospects.
ELV presents a compelling investment case with 71% analyst buy ratings and $445.13 price target offering 4.7% upside. However, declining 2026 profit margins to 2.46% and regulatory uncertainty in healthcare sector pose risks. The stock's current valuation at 18.81 P/E appears reasonable given earnings momentum and market position.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elevance Health Inc. Common Stock
Elevance Health provides health plans and healthcare services. Its offerings include medical, behavioral health, pharmacy, dental, vision, and complex-care solutions, including through the Carelon business.
Read more on ELV →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
